Interleukin-17A Promotes Esophageal Adenocarcinoma Cell Invasiveness Through ROS-dependent, NF-κB-mediated MMP-2/9 Activation.

Dong Liu,Rong Zhang,Jie Wu,Yansong Pu,Xiaoran Yin,Yan Cheng,Jing Wu,Cheng Feng,Yumei Luo,Jun Zhang

DOI: https://doi.org/10.3892/or.2017.5426

2017-01-01

Oncology Reports

Abstract:Interleukin-17A (IL-17A), a pro-inflammatory cytokine secreted primarily by Th17 cells, has been proved to be involved in the microenvironment of certain inflammation -related tumors. However, the role of IL-17A in cancer development has always been controversial. In this study, we investigated the effect of IL-17A on the regulation of esophageal adenocarcinoma (EAC) cell invasiveness and related molecular mechanism. Surface IL-17 receptor (IL-17R) expression on human EAC cell line OE19 was examined using flow cytometry. The effect of IL-17A on cell proliferation was measured by MTT assay. Cell migration and invasive ability in vitro were assessed by wound-healing and Matrigel-coated Transwell invasion assay. Intracellular reactive oxygen species (ROS) levels were determined by flow cytometry and fluorescence microscope. The protein expression levels of MMP-2, MMP-9, NF-kappa B and p-I kappa B-alpha were detected by western blotting. Our results showed that IL-17A promoted migration and invasion of OE19 cells in a dose-dependent manner, however it had less effect on OE19 cell proliferation. Furthermore, IL-17A treatment significantly upregulated the expression of MMP-2 and MMP-9, stimulated intracellular ROS production, increased I kappa B-alpha phosphorylation and NF-kappa B nuclear translocation. Nevertheless, IL-17A-induced expression of MMP-2/9 and OE19 cell invasiveness were both inhibited by pretreatment with N-acetyl-L-cysteine (NAC, a ROS scavenger) or pyrrolidine dithiocarbamate (PDTC, a NF-kappa B inhibitor). In conclusion, these findings demonstrate that IL-17A can promote the migration and invasiveness of EAC cells through ROS/NF-kappa B/MMP-2/9 signaling pathway activation, indicating that IL-17A may be a potential therapeutic target for EAC.